Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.
第一作者:
M,Graeser
第一单位:
West German Study Group, Moenchengladbach, Germany; Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany; Department of Obstetrics and Gynecology, University Witten/Herdecke, Witten, Germany. Electronic address: Monika.Graeser@wsg-online.com.
作者:
医学主题词
人类(Humans);乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);肿瘤辅助疗法(Neoadjuvant Therapy);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);中年人(Middle Aged);成年人(Adult);紫杉酚(Paclitaxel);老年人(Aged);随机对照试验(主题)(Randomized Controlled Trials as Topic);化学疗法, 辅助(Chemotherapy, Adjuvant);预后(Prognosis);随访研究(Follow-Up Studies)
DOI
10.1016/j.annonc.2025.07.016
PMID
40769278
发布时间
2025-11-01
- 浏览0
Annals of oncology
1366-1378页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



